Stock Screener App

Frei -

Installieren

Drug Manufacturers - General

92.57

1.62% 1.48

Gilead Sciences Inc (GILD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GILD? Forum Prognose Aktiensplit Dividendenhistorie

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

Gilead Sciences, Inc. (NASDAQ:GILD) Position Raised by Principal Financial Group Inc. - MarketBeat

Gilead Sciences to Present at Upcoming Investor Conference - Business Wire

Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold? - Yahoo Finance

Assembly Bio and Gilead collaborate to advance antiviral therapeutic programmes - Pharmaceutical Business Review

Gilead invests in Assembly Bio to advance clinical programs - The Pharma Letter

Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis - PMLiVE

Integrase Inhibitors Market Top PlayersGilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC. - openPR

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - Yahoo Finance

Gilead plans to halt free access to an HIV drug, worrying patient advocates - STAT

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Australia

Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com

(GILD)Analyzing Gilead Sciences's Short Interest - Benzinga

Gilead’s twice-yearly PrEP chosen as breakthrough of the year - Bay Area Reporter, America's highest circulation LGBT newspaper

Merck's HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies - Fierce Biotech

Gilead raises Assembly Bio stake to ~30% - MSN

Gilead recruits Terray in AI-driven drug discovery pact - OutSourcing-Pharma.com

Assembly Bio stock rises as Gilead ups stake (ASMB:NASDAQ) - Seeking Alpha

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding - MarketWatch

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead - MarketWatch

Xilio Therapeutics Secures $25M Investment from Gilead - TipRanks

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs - The Manila Times

Assembly Bio Secures $30.1M Gilead Investment, Advancing Ambitious Antiviral Pipeline - StockTitan

Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy - Medical Dialogues

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Page 22 | GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001 Trade Ideas — BCBA:GILD - TradingView

Insider Sell: Andrew Dickinson Sells 8,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus.com

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer - Yahoo Finance

Gilead and Terray Therapeutics collaborate on drug discovery - BioWorld Online

Gilead and Terray enter small molecule drug development deal - World Pharmaceutical Frontiers

Gilead, Terray Therapeutics announce research collaboration - Yahoo Finance

Gilead and Terray link to develop small-molecule therapies - Yahoo Finance

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure - Seeking Alpha

Andrew D. Dickinson Sells 8,500 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock - MarketBeat

Gilead Sciences CFO sells $781,660 in stock - Investing.com

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Gilead's New HIV Drug Aims For Global Impact By 2026 - Finimize

Gilead, Terray to collaborate on small molecule drugs (GILD:NASDAQ) - Seeking Alpha

FDA grants breakthrough status to Gilead's lung cancer drug - Investing.com

Gilead Sciences (GILD) Granted FDA Breakthrough Therapy Designation to Trodelvy - StreetInsider.com

(sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire

Gilead inks multi-target deal with Terray Therapeutics - The Pharma Letter

Fresh off $120M raise, AI-powered Terray is teaming up with Gilead in multi-pronged R&D pact - Fierce Biotech

Gilead Sciences, Terray Therapeutics Set AI-Powered Research Collaboration - MarketWatch

Gilead appoints Dietmar Berger as chief medical officer - PMLiVE

Gilead partners with Terray for AI-driven drug discovery - Investing.com India

AI-discovery partnership with Gilead will help Terray achieve its pipeline goals - FirstWord Pharma

Gilead Sciences (GILD) and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies - StreetInsider.com

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies - Business Wire

B. Riley Wealth Advisors Inc. Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch

New HIV prevention drug could reach poorest countries by 2025, says health official - Marketscreener.com

GILD Obtains Positive CHMP Opinion for Liver Disease Drug - Yahoo Finance

Gilead (GILD) Upgraded to Buy: Here's Why - Yahoo Finance

Gilead names Dietmar Berger CMO as it eyes R&D reset - Endpoints News

Gilead Sciences, Inc. (NASDAQ:GILD) Sees Large Increase in Short Interest - MarketBeat

Gilead Sciences' SWOT analysis: lenacapavir success fuels HIV stock growth - Investing.com India

Synovus Financial Corp Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Franklin Resources Inc. Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Analysts Set Gilead Sciences, Inc. (NASDAQ:GILD) PT at $96.43 - MarketBeat

Exome Asset Management LLC Purchases New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer - Indian Pharma Post

Gilead hires Dietmar Berger as CMO - BioCentury

Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know - Yahoo Finance

Gilead Brings In Sanofi’s Dietmar Berger To Reset Drug Development - News & Insights

EMA backs Merck’s Welireg, Bayer’s ATTR med and Gilead’s liver drug from $4.3B deal - FiercePharma

BMY

$57.33

1.83%

SNY

$47.71

0.44%

AMGN

$263.38

0.84%

PFE

$26.36

2.29%

NVS

$97.11

0.35%

MRK

$98.05

1.48%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters